Atriva is a mid-stage clinical development company with first-in-class host-targeting therapies to treat severe viral infections when prevention failed.
— Sachs Associates (@SachsAssociates) February 1, 2023
Meet Atriva at #Sachs_ELSF
More info @ https://t.co/hgPC4hy6UF#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing pic.twitter.com/xRVghanPdv